...A. Highlights: During 2021, continued to advance and expand Iovance tumor infiltrating lymphocyte (TIL) platform across multiple indications, including metastatic melanoma, cervical, head and neck, and non-small cell lung cancers. 1. 2. For lead TIL product candidate, lifileucel in metastatic melanoma, completed submission of additional information related to potency assays to FDA in support of planned Biologics License Application (BLA) submission. Resolution of potency assays with FDA is top priority for 2021. a. 3. Reported new and updated data from ongoing C-144-01 clinical study, demonstrating durable responses in Cohort 2 for one-time treatment of lifileucel. Cohort 2 data was presented at AACR 2021 and additional data of these will be presented at ASCO 2021. a. b. Additional indications, completed patient dosing in Cohort 2 for lifileucel in advanced cervical cancer. 4. For registration directed study of LN-145 in non-small cell lung cancer, continued to activate sites for IOV-LUN-202...